biostudies-literatureWilkins CRAmgenNCI NIH HHSNational Institutes of Healthe12701https://www.ebi.ac.uk/biostudies/studies/S-EPMC9087952biostudies-literatureUnknown6(3)<h4>Background</h4>Chemotherapy-induced thrombocytopenia (CIT) is common during treatment with antineoplastic therapies and may adversely impact chemotherapy dose intensity. There is no approved therapy for CIT. In our recent phase II randomized study, romiplostim led to correction of platelet counts in 85% of treated patients and allowed resumption of chemotherapy, with low rates of recurrent CIT in the first two cycles or 8 weeks of chemotherapy. However, there is a lack of long-term data on the efficacy and safety of romiplostim in CIT.<h4>Objectives</h4>To analyze efficacy and safety of romiplostim in the patients in the phase 2 study, who received romiplostim for ≥1 year.<h4>Patients/methods</h4>Twenty-one patients remained on romiplostim for ≥1 year. We analyzed the effect of romiploResearch and practice in thrombosis and haemostasisRomiplostim for chemotherapy-induced thrombocytopenia: Efficacy and safety of extended use.PMC9087952P30 CA008748Wilkins CROrtiz JMones JVSoff GAYin SGilbert LJMantha SParameswaran RfalseRomiplostim for chemotherapy-induced thrombocytopenia: Efficacy and safety of extended use.<h4>Background</h4>Chemotherapy-induced thrombocytopenia (CIT) is common during treatment with antineoplastic therapies and may adversely impact chemotherapy dose intensity. There is no approved therapy for CIT. In our recent phase II randomized study, romiplostim led to correction of platelet counts in 85% of treated patients and allowed resumption of chemotherapy, with low rates of recurrent CIT in the first two cycles or 8 weeks of chemotherapy. However, there is a lack of long-term data on the efficacy and safety of romiplostim in CIT.<h4>Objectives</h4>To analyze efficacy and safety of romiplostim in the patients in the phase 2 study, who received romiplostim for ≥1 year.<h4>Patients/methods</h4>Twenty-one patients remained on romiplostim for ≥1 year. We analyzed the effect of romiplo2022-01-01T00:00:00Z2022 Mar2025-05-18T12:04:49.281Z2025-04-05T20:38:33.985ZS-EPMC90879523558203810.1002/rth2.12701